INTRODUCTION AND OBJECTIVES:
Little is known about treatment for locally very advanced prostate cancer (PCa) with invasion of the bladder or rectum. Our data report on potentially unresectable PCa, which is subjected to a short period of neoadjuvant androgen deprivation therapy (ADT) with the intent to radical prostatectomy (RP) if favorable response is achieved.
METHODS: We retrospectively analyzed the data of 31 men, who showed invasion of the bladder (n [ 20) and/or rectum (n [ 17) in clinical examination (DRE and TRUS, n [ 12), imaging (MRI or CT, n [ 27) and/or cystoscopy/rectoscopy with biopsy (n [ 3). All patients underwent a short period of neoadjuvant ADT (median 3 months) before repeat imaging (MRI or CT) was performed. Oncological outcomes included biochemical recurrence (BCR), metastatic progression (MP) and prostate cancer specific mortality (PCSM).
RESULTS: Overall, 77.4% showed at least partial local response in repeat imaging. Clinical T4 stage was still seen in seven patients (bladder [ 3; rectal [ 5, both [ 1) . In five patients, repeat imaging demonstrated stable disease, while two patients showed progressive disease. In one, testosterone levels were not adequately suppressed and consequently complete androgen blockade (CAB) initiated. Another three months later, confirmation imaging revealed partial response. The second progressive patient had developed distant bone metastases and underwent chemotherapy. RP was performed in 26 patients. Median operative time was 205 min and median catheterization time was 14 days. Two major Clavien IIIb complications were documented (one rectal injury and one ureter injury requiring surgery). Median follow-up was 22 months (IQR: 18-30). One-year BCR-free and MP-free survival rates were 56.7% as well as 73.9%.
CONCLUSIONS: Among potentially unresectable PCa patients, a short period of neoadjuvant ADT led to partial local response in 77.4%. However, although RP was feasible, the oncological benefit remains questionable. -up (N[40) were excluded. Biochemical recurrence (BCR) was defined as PSA>0.2 ng/ml after RP. Likelihood of ART treatment per NCCN guidelines, BCR, prostate cancer specific mortality (PCSM) and overall mortality (OM) were the outcomes. 2016 Medicare reimbursement rates were used to estimate cost of secondary interventions.
RESULTS: BCR occurred in 321 (21.99%) patients; at a median follow-up data of 4.9 years. 81% had follow-up PSA over 2 years. Per NCCN guidelines, 532 (36.44%) men were indicated to undergo ART. However, of these men, only 240 (45.11%) had BCR and 17 (1.16%) of them went through ART; the remainder had no evidence of disease. Despite the low proportion of patients undergoing ART, the overall and prostate cancer specific mortality in this cohort are similar to others: 84 (5.75%) and 23 (1.58%), respectively. At a Medicare expense of $37,000 per ART treatment, treating per NCCN guidelines would result in a surplus of $10 million for the treatment of patients with no evidence of disease.
CONCLUSIONS: 69-71% is the range of risk that patients who have unfavorable pathological features may be over treated by ART. Previous reports of SRT have similar outcomes and may reduce the cost that are supported by these outcomes. The results of this study can provide a fundamental evidence for future trials on utilization of SRT.
